The Enhancing Effect of γ-Cyclodextrin Inclusion on γ-Tocotrienol-dependent Negative Growth Control of Mesothelioma Cells in a Xenograft Model
DOI:
https://doi.org/10.31989/ffhd.v1i12.110Abstract
Background: Malignant mesothelioma is an aggressive cancer with no effective treatment options. Of phytochemicals, tocotrienol (T3), a member of vitamin E, is one of the most potent anti-mesothelioma agents, but the effectiveness in vivo is quite limited, due to its low bioavailability. In this study, we investigated if the oral treatment of γ-T3 inclusion with γ-cyclodextrin (CD) could improve the bioavailability and anticancer activity of the T3.
Findings: Using nude mice bearing MSTO-211H cells (a human malignant mesothelioma cell line), the effect of γ-T3 inclusion with γ-CD on γ-T3 level in tumor tissues, tumor growth, and its related mRNA levels were examined. The difference of tumor growth between the two groups had no statistical significance, but the latter showed a lower tendency compared with the former. In linked with this observation, the level of vascular endothelial growth factor mRNA required for in vivo tumor growth in γ-T3 inclusion with γ-CD group was lower than that in γ-T3 group, on the contrary, the level of γ-T3 level showed an opposite tendency.
Conclusion: Our study demonstrated that the bioavailability of γ-T3 was improved by an oral administration of a novel γ-T3 inclusion complex with CD. Furthermore, the improvement of the bioavailability contributed to the increase of anticancer activity of γ-T3 in vivo.
Keywords: Anti-cancer agent, bioavailability, cyclodextrin, mesothelioma, tocotrienol.
Downloads
Published
Issue
Section
License
Any manuscripts or substantial parts of it, submitted to the journal must not be under consideration by or previously published in any other journal or citable form. Authors are required to ensure that no material submitted as part of a manuscript infringes existing copyrights or the rights of a third party. In submitting one's article in any form, the author has assigned the FFC publishing rights and has agreed to an automatic transfer of the copyright to the publisher. This is so that the FFC may create print option journals, for example, at the FFC’s discretion. If the author wishes to distribute their works by means outside of the FFC, for example within their community, they will have to place a request.
Correspondence concerning articles published in Functional Foods in Health and Disease is encouraged. While derivative works (adaptations, extensions on the current work, etc.) are allowed, distribution of the modified material is not allowed without permission from the FFC.